Seattle & Northwest CRE News In Your Inbox.
Sign up for Connect emails to stay informed with CRE stories that are 150 words or less.
Sonoma Bio Signs Long-Term Lease for New Seattle R&D Center
Cushman & Wakefield and JLL have jointly represented Sonoma Biotherapeutics, Inc in a lease agreement to develop an 83,000-square-foot Research and Development (R&D) and Manufacturing Center in Seattle. The complex, owned by Office Properties Income Trust and being redeveloped by The RMR Group, will be called Unison Elliot Bay.
Bay Area-based Sonoma Bio, a clinical-stage biotech company focused on developing engineered regulatory T cell therapies for autoimmune and inflammatory diseases, will be the anchor tenant. Cushman & Wakefield Managing Director Steve Lico and JLL Managing Director Kris Richey Curtis represented Sonoma Bio in the transaction, while Tim Jones and Joe Gowan of JLL represented RMR.
“This Center will create highly-skilled scientific, engineering and manufacturing jobs in the Seattle area, taking advantage of the deep local capabilities and expertise. As we move into the next phase of growth, we want to unite talent across the life science communities of Seattle and San Francisco,” said Sonoma Bio CEO Jeff Bluestone.
Rendering Courtesy of The RMR Group
- ◦Lease
- ◦Development
